Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105524 | 0.87 | POLB (0.75) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL1999759 | 0.84 | POLB (0.71) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL3928781 | 0.83 | POLB (0.69) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL232841 | 0.83 | POLB (0.69) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL14136353 | 0.83 | SMN1; SMN2 (0.70) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL25310714 | 0.82 | POLB (0.68) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL14500079 | 0.82 | POLB (0.68) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2966520 | 0.82 | POLB (0.68) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL2006539 | 0.81 | POLB (0.66) | POLBSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL12267527 | 0.81 | POLB (0.66) | POLBSMN1; SMN2LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725538-B1 | PYRIDAZINONE UREAS AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-29 | — | — | EP | claimed |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | JANSSEN PHARMACEUTICA,N.V. (BE) | 2005-09-22 | — | — | US | claimed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| EP-1725538-B1 | PYRIDAZINONE UREAS AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-29 | — | — | EP | disclosed |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | JANSSEN PHARMACEUTICA,N.V. (BE) | 2005-09-22 | — | — | US | disclosed |
| EP-1069124-B1 | 2-Benzimidazolylamine compounds as ORL1-receptor agonists | PFIZER (US) | 2004-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | POLB 4090/4885SMN1; SMN2 2275/4885LMNA 3577/4885 |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | POLB 2920/4885SMN1; SMN2 4722/4885LMNA 4314/4885 |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | ITGA4, ITGB4, ITGB7 | POLB 2837/4885SMN1; SMN2 3062/4885LMNA 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.